TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06371417: Phase 1b Open-label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial)

Sponsor: Chugai Pharmaceutical · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 144 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$281,520

Rescue Site Savings

+$187,680

Unlock Full NCT06371417 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06371417 Rescue Dossier →